| Project item | Indications | Research phase | Cooperation demands |
| BDA202204 | “hard-to-treat” solid tumors (pancreatic, gastric, etc) | License-out or co-development | License-out or co-development |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TR2-R52H9 | Rabbit | Rabbit TROP-2 / TACSTD2 Protein, His Tag |  |
||
| TR2-H82Ea | Human | Biotinylated Human TROP-2 / TACSTD2 (88-274) Protein, His,Avitag™ |  |
|
|
| MBS-K028 | Human | Human TROP-2-coupled Magnetic Beads | |||
| TR2-C52H4 | Canine | Canine TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-R52H3 | Rhesus macaque / Cynomolgus | Rhesus macaque / Cynomolgus TROP-2 / TACSTD2 Protein, His Tag (MALS verified) |  |
|
|
| TR2-M52H6 | Mouse | Mouse TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-H5253 | Human | Human TROP-2 / TACSTD2 Protein, Fc Tag |  |
|
|
| TR2-H82E5 | Human | Biotinylated Human TROP-2 / TACSTD2 Protein, His,Avitag™ |  |
|
|
| TR2-H5223 | Human | Human TROP-2 / TACSTD2 Protein, His Tag (MALS verified) |  |
|
|
Immobilized 32.6 μg TROP-2/1 mg beads can bind Anti-TROP-2 mAb with an EC50 of 0.8505 μg/mL (QC tested).
The purity of Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) is more than 85% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | GS-0132; IMMU-132; TROP-2-SN-38; IMMU0132 | Approved | Immunomedics Inc | Trodelvy, 拓达维 | Mainland China | Triple Negative Breast Neoplasms | Everest Medicines (Suzhou) Inc | 2020-04-22 | Carcinoma, Ovarian Epithelial; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Brain metastases; Endometrial Neoplasms; Metastatic breast cancer; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| FDA018 Antibody Drug Conjugate | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details | |
| BIO-106 | BIO-106 | Hangzhou Baikai Biopharmaceutical Co Ltd | Neoplasms | Details | |
| PF-06664178 | PF06664178; PF-06664178 | Pfizer Inc | Details | ||
| DAC-002 | JS-108; DAC-002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma | Details |
| 重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
| SKB-264 | SKB-264 | Phase 3 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SHR-A1921 | SHR-A1921; SHRA1921 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours | Details |
| Datopotamab deruxtecan | Dato-DXd; DS-1062a; DS-1062 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BL-M02D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
